In vivo electrophysiological assessment of the putative antidepressant Wf-516 in the rat raphe dorsalis, locus coeruleus and hippocampus

Naunyn-Schmiedeberg's Archives of Pharmacology

Volumn 376, Issue 5, 2008, Pages 351-361

  El Mansari, M ^a   Blier, P ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

Author keywords

Antidepressant; Hippocampus; Locus coeruleus; Norepinephrine; Raphe dorsalis; Serotonin

Indexed keywords

1 [4 (3,4 DICHLOROPHENYL)PIPERIDIN 1 YL] 3 [2 (5 METHYL 1,3,4 OXADIAZOL 2 YL)BENZO[B]FURAN 4 YLOXY]PROPAN 2 OL; 2 DIPROPYLAMINO 8 HYDROXYTETRALIN; 4 IODO 2,5 DIMETHOXYAMPHETAMINE; ANTIDEPRESSANT AGENT; LYSERGIDE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; NORADRENALIN; SEROTONIN; SEROTONIN 1A ANTAGONIST; SEROTONIN 1A RECEPTOR; SEROTONIN 2A ANTAGONIST; UNCLASSIFIED DRUG; VOLINANSERIN; WF 516;

ANIMAL CELL; ARTICLE; BRAIN ELECTROPHYSIOLOGY; CONTROLLED STUDY; DORSAL RAPHE NUCLEUS; HIPPOCAMPUS; INTRACELLULAR RECORDING; LOCUS CERULEUS; MALE; MICROELECTRODE; MICROIONTOPHORESIS; NERVE CELL INHIBITION; NONHUMAN; RAT; RECEPTOR BLOCKING; SEROTONINERGIC NERVE CELL;

ANIMALS; ANTIDEPRESSIVE AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; ELECTROPHYSIOLOGY; HIPPOCAMPUS; INJECTIONS, INTRAVENOUS; LOCUS COERULEUS; MALE; MICROELECTRODES; NEURONS; OXADIAZOLES; PIPERIDINES; RAPHE NUCLEI; RATS; RATS, SPRAGUE-DAWLEY; RECEPTOR, SEROTONIN, 5-HT1A; RECEPTOR, SEROTONIN, 5-HT2A; SEROTONIN;

EID: 37749054640     PISSN: 00281298     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00210-007-0210-6     Document Type: Article

References (43)

1. 1A receptor gene. J Biol Chem 265:5825-5832
2. Artigas F, Perez V, Alvarez E (1994) Pindolol induces a rapid improvement of depressed patients treated with serotonin reuptake inhibitors. Arch Gen Psychiatry 51:248-251
3. Artigas F, Adell A, Celada P (2006) Pindolol augmentation of antidepressant response. Curr Drug Targets 7:139-147
4. Ballesteros J, Callado LF (2004) Effectiveness of pindolol plus serotonin uptake inhibitors in depression: a meta-analysis of early and late outcomes from randomized controlled trials. J Affect Disord 79:137-147
5. Béïque JC, de Montigny C, Blier P, Debonnel G (1998) Blockade of 5-hydroxytryptamine and noradrenaline uptake by venlafaxine: a comparative study with paroxetine and desipramine. Br J Pharmacol 125:526-532
6. Béïque JC, de Montigny C, Blier P, Debonnel G (1999) Venlafaxine: discrepancy between in vivo 5-HT and NE reuptake blockade and affinity for reuptake sites. Synapse 32:198-211
7. Bel N, Artigas F (1992) Fluvoxamine preferentially increases extracellular 5-hydroxytryptamine in the raphe nuclei: an in vivo microdialysis study. Eur J Pharmacol 229:101-103
8. Blier P, Bergeron R (1995) Effectiveness of pindolol with selected antidepressant drugs in the treatment of major depression. J Clin Psychopharmacol 15:217-222
9. 1A receptors without altering 5-HT autoreceptor sensitivity: an electrophysiological study in the rat brain. Synapse 1:225-232
10. Blier P, de Montigny C (1994) Current advances and trends in the treatment of depression. Trends Pharmacol Sci 15:220-226
11. Blier P, Ward H (2002) Toward optimal treatments for major depression. CNS Spectr 7:148-150
12. 1A receptors in the dorsal raphe and hippocampus: II. Effect of pertussis and cholera toxins. J Pharmacol Exp Ther 265:16-23
13. 2 agonist augments γ-aminobutyric acid and excitatory amino acid inputs to noradrenergic locus coeruleus neuron. Neuroscience 54:409-420
14. Clerc GE, Ruimy P, Verdeau-Pallas J (1994) A double-blind comparison of venlafaxine and fluoxetine in patients hospitalized for major depression and melancholia. The venlafaxine French inpatients study group. Int Clin Psychopharmacol 9:139-143
15. Deecher DC, Beyer CE, Johnston G, Bray J, Shah S, Abou-Gharbia M, Andree TH (2006) Desvenlafaxine succinate: A new serotonin and norepinephrine reuptake inhibitor. J Pharmacol Exp Ther 318:657-665
16. Dremencov E, El Mansari M, Blier P (2007) Noradrenergic augmentation of escitalopram response by risperidone: electrophysiological studies in the rat brain. Biol Psychiatry 61:671-678
17. El Mansari M, Blier P (1997) In vivo electrophysiological characterization of 5-HT receptors in the guinea pig head of caudate nucleus and orbitofrontal cortex. Neuropharmacology 36:577-588
18. Fletcher A, Forster EA, Bill DJ, Brown G, Cliffe IA, Hartley JE, Jones DE, McLenachan A, Stanhope KJ, Critchley DJ, Childs KJ, Middlefell VC, Lanfumey L, Corradetti R, Laporte AM, Gozlan H, Hamon M, Dourish CT (1996) Electrophysiological, biochemical, neurohormonal and behavioural studies with WAY-100635, a potent, selective and silent receptor antagonist. Behav Brain Res 73:337-353
19. 1A receptor antagonist, WAY-100635. Eur J Pharmacol 281:81-88
20. Gharabawi G, Canuso C, Pandina G, Bossie C, Kujawa M, Kosik-Gonzalez, Turkoz I, Mahmoud R, Shelton R (2006a) Risperidone treatment of resistant depression: a double-blind randomized trial. Neuropsychopharmacology 31:S228
21. Gharabawi G, Canuso C, Pandina G, Bossie C, Kujawa M, Kosik-Gonzalez, Turkoz I (2006b) A double-blind placebo-controlled study of adjunctive risperidone for treatment-resistant major depressive disorder. Eur Neuropsychopharmacol 16:S562
22. 1A receptors in depression and anxiety. Raven, New York, pp 35-53
23. 1A receptor antagonists NAN-190 and BMY 7378 are partial agonists in the rat dorsal raphe nucleus in vitro. Eur J Pharmacol 211:211-219
24. Haddjeri N, de Montigny C, Blier P (1997) Modulation of the firing activity of noradrenergic neurons in the rat locus coeruleus by the 5-hydroxytryptamine system. Br J Pharmacol 120:865-875
25. Haddjeri N, de Montigny C, Blier P (1999) Modulation of the firing activity of rat serotonin and noradrenaline neurons by (±)pindolol. Biol Psychiatry 45:1163-1169
26. Kandel ER, Spencer WA (1961) Electrophysiology of hippocampal neurons. II. After potentials and repetitive firing. J Neurophysiol 24:243-259
27. Maeda J, Morio Y, Oohashi Y, Katayama J, Nishiyama A, Yamagami K, Saito K (2006a) Wf-516, a novel antidepressant with dual serotonergic activity: l. Receptorial and pharmacological profiles in comparison with reference antidepressants. Eur Neuropsychopharmacol 16:S333
28. Maeda J, Morio Y, Katayama J, Horie S, Inaba K, Nishiyama A, Eguchi J, Saito K (2006b) Wf-516, a novel antidepressant with dual serotonergic activity: II. Pharmacological profiles ex vivo and in vivo to monoamine transporters in comparison with standard antidepressant. Eur Neuropsychopharmacol 16:S333
29. Millan MJ, Gobert A, Lejeune F, Newman-Tancredi A, Rivet JM, Auclair A, Peglion JL (2001) S33005, a novel ligand at both serotonin and norepinephrine transporters: I. Receptor binding, electrophysiological, and neurochemical profile in comparison with venlafaxine, reboxetine, citalopram, and clomipramine. J Pharmacol Exp Ther 298:565-580
30. Nelson JC, Mazure CM, Jatlow PI, Bowers MB, Price LH (2004) Combining norepinephrine and serotonin reuptake inhibition mechanisms for treatment of depression: a double-blind, randomized study. Biol Psychiatry 55:296-300
31. 1A receptors and inhibitor of 5-HT reuptake, in a chronic mild stress model of depression in rat. Eur Neuropsychopharmacol 16:S305
32. Piňeyro G, Blier P (1999) Autoregulation of serotonin neurons: role in antidepressant drug action. Pharmacol Rev 51:533-591
33. Piñeyro G, Blier P, Dennis T, de Montigny C (1994) Desensitization of the neuronal 5-HT carrier following its long-term blockade. J Neurosci 14:3036-3047
34. Poirier MF, Boyer P (1999) Venlafaxine and paroxetine in treatment-resistant depression. Double-blind, randomized comparison. Br J Psychiatry 175:12-16
35. Ranck JB (1975) Behavioral correlates and firing repertoires of neurons in the dorsal hippocampal formation and septum of unrestrained rats. In: Isaacson RL, Pribram KH (eds) The Hippocampus. Plenum, New York, pp 207-244
36. Rapaport MH, Gharabawi GM, Canuso CM, Mahmoud RA, Keller MB, Bossie CA, Turkoz I, Lasser RA, Loescher A, Bouhours P, Dunbar F, Nemeroff CB (2006) Effects of risperidone augmentation in patients with treatment-resistant depression: results of open-label treatment followed by double-blind continuation. Neuropsychopharmacology 31:2505-2513
37. 1A receptors: in vivo microdialysis and electrophysiological studies in the rat brain. Neuropsychopharmacology 15:349-360
38. Seager MA, Barth VN, Phebus LA, Rasmussen K (2005) Chronic coadministration of olanzapine and fluoxetine activates locus coeruleus neurons in rats: implications for bipolar disorder. Psychopharmacology (Berl) 181:126-133
39. Shelton RC, Tollefson GD, Tohen M, Stahl S, Gannon KS, Jacobs TG, Buras WR, Bymaster FP, Zhang W, Spencer KA, Feldman PD, Meltzer HY (2001) A novel augmentation strategy for treating resistant major depression. Am J Psychiatry 158:131-134
40. 2A receptor antagonism on the firing activity of norepinephrine neurons. J Pharmacol Exp Ther 302:983-991
41. Szabo ST, de Montigny C, Blier P (1999) Modulation of noradrenergic neuronal firing by selective serotonin reuptake blockers. Br J Pharmacol 126:568-571
42. Tada K, Kasamo K, Ueda N, Suzuki T, Kojima T, Ishikawa K (1999) Anxiolytic 5-hydroxytryptamine1A agonists suppress firing activity of dorsal hippocampus CA1 pyramidal neurons through a postsynaptic mechanism: single-unit study in unanesthetized, unrestrained rats. J Pharmacol Exp Ther 288:843-848
43. 2A receptor-mediated head shakes in rats. Psychopharmacology (Berl) 119:9-14